Mark Borchelt, MD
Endocrinology, Diabetes & Metabolism · Gulfport, MSNPI 1194776286
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $518,312 of the $722,268 with a category attached, or 71.8%. 57 manufacturers reported payments, led by Lilly USA, LLC at 49.2% of the total. Reporting peaked in 2022 at $175,870 and has fallen 64.4% since, to $62,572 in 2025. Among endocrinology, diabetes & metabolism clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,689 payments — averaging $268.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$355K
- Novo Nordisk$90K
- GRT US Holding, Inc.$87K
- Amgen$57K
- Averitas Pharma Inc.$27K
- Corcept Therapeutics$26K
- plus $80K from 51 others
Across 122 payments — averaging $2807.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$271K
- Boehringer Ingelheim$29K
- AbbVie$19K
- Intercept Pharmaceuticals, Inc.$17K
- Boehringer Ingelheim International GmbH$3K
- Chiasma, Inc.$2K
- plus $1K from 1 others
What the payments were for
- Consulting fees$20,8753%
- Speaking & faculty fees$518,31272%
- Travel & lodging$138,44819%
- Food & beverage$44,3756%
- Education$2580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$154,043
- Qutenza$110,546
- TRULICITY$96,762
- Ozempic$58,319
- JARDIANCE$42,348
- EVENITY$40,533
- Korlym$24,508
- JATENZO$23,219
- RYBELSUS$21,113
- BAQSIMI$20,875
- INVOKANA$19,539
- Prolia$14,115
- Kerendia$7,277
- Tresiba$3,335
- Xultophy 100/3.6$2,633
- INPEN SMART INSULIN DELIVERY SYSTEM$753
- FreeStyle Libre$729
- InPen$653
- iLet Bionic Pancreas$647
- FARXIGA$587
How this compares
$722,268 in reported general payments places this provider in the 95th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 24 | $1,762,341 |
| MounjaroTirzepatide | 701 | $925,509 |
| OzempicSemaglutide | 556 | $854,436 |
| JardianceEmpagliflozin | 502 | $605,837 |
| TrulicityDulaglutide | 320 | $450,113 |
| Tresiba Flextouch U-200Insulin Degludec | 345 | $359,366 |
| ForteoTeriparatide | 31 | $130,327 |
| ProliaDenosumab | 65 | $112,160 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 97 | $106,402 |
| FarxigaDapagliflozin Propanediol | 110 | $94,745 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 39 | $56,511 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $52,258 |
| SynjardyEmpagliflozin/Metformin Hcl | 52 | $52,202 |
| KerendiaFinerenone | 61 | $49,674 |
| RybelsusSemaglutide | 28 | $45,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $26,115 | $1,762,34124 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Humatrope | $355,117 | $1,555,4961,096 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $89,560 | $920,455654 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $23,634 | $788,721681 claims |
| AmgenProlia, Evenity (2 Syringes) | $57,304 | $150,41181 claims |
| AstraZenecaFarxiga | $1,452 | $94,745110 claims |
| Johnson & JohnsonInvokana, Invokamet | $20,476 | $61,47339 claims |
| BayerKerendia | $8,522 | $49,67461 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,035 | $22,89420 claims |
| AbbVieSynthroid | $309 | $21,213235 claims |
| MerckJanuvia | $620 | $15,41015 claims |
| Esperion Therapeutics, Inc.Nexletol | $75 | $9,49918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Gulfport
- Ellen CaswellGulfport$5K
- Eric DyessJackson$885K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
- Amanda SchieferJackson$204K
- Delali BlavoSouthaven$148K
- Richard GallowayHattiesburg$109K
- James PowellHattiesburg$88K
- John SistrunkJackson$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.